Jens Haenig

Global Scientific Director
Novartis Pharma AG
Basel, Basel-Stadt, Switzerland

Presentation(s):

• PB0716 - VAYHIT: A clinical trial program evaluating the efficacy and safety of the anti-B-cell-activating factor receptor (BAFF-R)/B-cell-depleting monoclonal antibody ianalumab in patients with primary ITP

  Monday, June 24, 2024
  13:45 – 14:45 ICT